Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Tenet Healthcare (NYSE: THC) Volume Spotlight: What the Latest Filings Show on Second Quarter Income, Contract Termination Revenue and 2026 Guidance

Tenet Healthcare Corporation (NYSE: THC) shares were trading at USD 259.51 on October 27, 2026, down 3.51%, with a relative volume at time of 4.18. The hospital and ambulatory care operator filed its Form 10-Q for the quarter ended June 30, 2026 on July …

Nitish Kishor | 27 October 2026

Universal Health Services (NYSE: UHS) Volume Stands at 4.82 Relative: What the Latest Filings Show on Second Quarter Revenues and the Talkspace Agreement

Universal Health Services, Inc. (NYSE: UHS) shares were trading at USD 174.23 on October 27, 2026, down 6.18%, with a relative volume at time of 4.82. The hospital operator agreed to acquire Talkspace on March 9, 2026, acquired Irish residential facilities in July 2026, …

Nitish Kishor | 27 October 2026

What Absci (NASDAQ:ABSI) Investors Should Know as Shares Climb 12% on ABS-201 Half-Life Data

Absci (NASDAQ:ABSI) shares are trading up 11.64% to $10.55 as investors stay focused on the ABS-201 hair-loss program after positive interim Phase 1 data. The data showed an estimated antibody half-life of at least 65 days. Shares opened at $9.45, and the 52-week range …

Nitish Kishor | 27 October 2026

Avalyn Pharma (NASDAQ:AVLN) Slips 5% as IPO Lock-Up Expiry Opens the Door to More Supply

Avalyn Pharma (NASDAQ:AVLN) shares are trading down 5.39% to $25.68 after the lock-up period following its April IPO expired. The lock-up covered roughly 25.2 million common shares, plus stock options and warrants, held by directors, executive officers and holders of substantially all outstanding stock. …

Nitish Kishor | 27 October 2026

Butterfly Network (NYSE:BFLY) Rallies 10% Ahead of Thursday's Third-Quarter Earnings Report

Butterfly Network (NYSE:BFLY) shares are trading up 10.14% to $7.34 as investors position ahead of its third-quarter earnings report, due before the market opens on Thursday. The company also announced it will present at the UBS Global Healthcare Conference on November 10. No new …

Nitish Kishor | 27 October 2026

Ginkgo Bioworks (NYSE:DNA) Rises 11% on Reported Collaboration With an Agenus Subsidiary

Ginkgo Bioworks (NYSE:DNA) shares are trading up 11.33% to $11.16 after a report that a subsidiary of Agenus (NASDAQ:AGEN) signed a collaboration agreement with the company. The report gave no deal terms, so the details and financial impact are unclear. Shares opened at $10.12, …

Nitish Kishor | 27 October 2026

HCA Healthcare (NYSE:HCA) Slides 4% Despite Third-Quarter Beat and Upper-Half Guidance

HCA Healthcare (NYSE:HCA) shares are trading down 4.03% to $446.50 after the hospital operator reported third-quarter results that beat estimates but carried a clear payer mix cost. Adjusted EPS of $7.22 compared with roughly $6.65 expected, and revenue of $19.849 billion topped expectations near …

Nitish Kishor | 27 October 2026

Why Is ImmunityBio (NASDAQ:IBRX) Stock Up 10% as Biotech Takeover Speculation Builds?

ImmunityBio (NASDAQ:IBRX) shares are trading up 9.50% to $8.55, rebounding from a four-session losing streak that ended with Monday's close at $7.81. A television market commentator described the stock as a promising speculative play and pointed to a wave of biotech takeovers, which renewed …

Nitish Kishor | 27 October 2026

A Quiet Rebound: Inhibrx Biosciences (NASDAQ:INBX) Climbs 9% With No Company News in Sight

Inhibrx Biosciences (NASDAQ:INBX) shares are trading up 9.29% to $96.84, rebounding after slipping below the 200-day moving average of about $91.47 on Monday, when the stock closed near $88.61. The stock is now back above that level and near its 50-day average of $103.80. …

Nitish Kishor | 27 October 2026

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Surges 23% After Q3 Beat and Higher ARCALYST Guidance

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) shares are trading up 22.98% to $89.75 after a third-quarter report that beat expectations on revenue and earnings. ARCALYST revenue rose about 58% from a year earlier to $286.0 million, ahead of an estimate near $260.7 million. Adjusted EPS of …

Nitish Kishor | 27 October 2026
Support

Hi! How can we help you today?

Loading…